摘要
背景:VDAC(电压依赖性阴离子选择性通道)是位于线粒体外膜的丰富的成孔蛋白的小家族。它们的作用范围从最直观的,由于其β-桶结构而形成的亲水导管通过膜,至少被了解的功能,使得它们在生物能量代谢和细胞溶质成分之间的相互作用中是必不可少的参与者。由于这种定位,VDAC1尤其被报道涉及细胞凋亡,己糖激酶和微管蛋白结合以及Warburg效应。由于这些原因,VDAC参与癌症被认为是必然的,并且已经提出并且在实验性试验中使用了许多化合物来证明影响VDAC功能的分子的功效。 目标:在这项工作中,我们从而通过VDAC调查描述药物化合物作用于癌症增殖的文献。分为三类:分子作用于VDAC-Hexokinase结合,直接抑制VDAC电导的分子,影响VDAC基因表达水平的分子。还考虑了用于此目的的生物肽的应用。 结论:由于对VDAC蛋白功能特性的认识仍然不足,VDAC作为抗癌药物的靶点仍然是一个非常开放而且非常有前景的领域。
关键词: VDAC,线粒体功能障碍,癌症,细胞凋亡,己糖激酶,warburg效应,线粒体外膜。
Current Medicinal Chemistry
Title:Anti-Cancer Compounds Targeted to VDAC: Potential and Perspectives
Volume: 24 Issue: 40
关键词: VDAC,线粒体功能障碍,癌症,细胞凋亡,己糖激酶,warburg效应,线粒体外膜。
摘要: Background: VDAC (Voltage-Dependent Anion selective Channel) is a small family of abundant pore-forming proteins located in the outer mitochondrial membrane. Their role range from the most intuitive, the formation of a hydrophilic conduit through the membrane thanks to its beta-barrel structure, to less understood functions that make them essential actors in the cross-talk between the bioenergetics metabolism and the cytosol components. Due to this localization, VDAC1, in particular, has been reported to be involved in apoptosis, Hexokinase and tubulin binding, and in the Warburg effect. For these reasons, an involvement of VDAC in cancer is considered consequential and a number of compounds have been proposed and used in experimental trials to demonstrate the efficacy of molecules affecting the functions of VDAC.
Objectives: In this work, we thus survey the literature describing drug compounds acting on the cancerous proliferation through VDAC. Three main categories have been assigned: molecules acting on the VDAC-Hexokinase binding, molecules directly inhibiting the VDAC conductance, molecules affecting the expression levels of the VDAC gene. The application of biological peptides for this purpose is also considered.
Conclusion: Since the knowledges about the functional properties of VDAC protein are still insufficient, VDAC as a pharmacological target in the fight against cancer is still a very open, but very promising, field.
Export Options
About this article
Cite this article as:
Anti-Cancer Compounds Targeted to VDAC: Potential and Perspectives, Current Medicinal Chemistry 2017; 24 (40) . https://dx.doi.org/10.2174/0929867324666170530074039
DOI https://dx.doi.org/10.2174/0929867324666170530074039 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metastatic Cancer Stem Cells: New Molecular Targets for Cancer Therapy
Current Pharmaceutical Biotechnology An Overview on the Different Approaches to Obtain Luminescent Hydrotalcite Nanoparticles and Films
Current Physical Chemistry The Role of the Healthy Dietary Intake in Women with Human Papilloma Virus
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Regulation of Endothelial Cell Death and Its Role in Angiogenesis and Vascular Regression
Current Neurovascular Research Dendrimers in Photodynamic Therapy
Current Medicinal Chemistry MicroRNA Targeting as a Therapeutic Strategy Against Glioma
Current Molecular Medicine Current Developments Using Emerging Transdermal Technologies In Physical Enhancement Methods.
Current Drug Delivery Current Targets for Anticancer Drug Discovery
Current Drug Targets Relaxin Receptors - New Drug Targets for Multiple Disease States
Current Drug Targets The Role of SHP-2 in Cell Signalling and Human Disease
Current Enzyme Inhibition Interplay of β-Catenin with Xenobiotic-Sensing Receptors and its Role in Glutathione S-Transferase Expression
Current Drug Metabolism Recent Advances in the Therapeutic Perspectives of Nutlin-3
Current Pharmaceutical Design Treatment of Pulmonary Edema by ENaC Activators/Stimulators
Current Molecular Pharmacology Emerging Therapies in Chronic Myeloid Leukemia
Current Cancer Drug Targets Tumoral Drug Metabolism: Perspectives and Therapeutic Implications
Current Drug Metabolism p53 Gene Family: Structural, Functional and Evolutionary Features
Current Genomics Applications of HPLC-MALDI-TOF MS/MS Phosphoproteomic Analysis in Oncological Clinical Diagnostics
Current Proteomics Cell Cycle Regulatory Protein 5 (Cdk5) is a Novel Downstream Target of ERK in Carboplatin Induced Death of Breast Cancer Cells (Supplementary Data)
Current Cancer Drug Targets MicroRNA-34a and its target genes: Key factors in cancer multidrug resistance
Current Pharmaceutical Design Targeted Therapy of Breast Cancer
Current Pharmaceutical Design